the Eikon terminal provides customers access to Refinitiv’s dominant foreign-exchange trading venues. Moreover, we anticipate LSEG to invest in its trading and banking solutions segment ...

Eikon Therapeutics, a company headed by the former Merck executive who steered the cancer drug Keytruda to FDA approval, has raised $350.7 million to support a pipeline that includes a lead drug ...

Eikon Therapeutics is no stranger to eye-popping funding rounds, and the cancer-focused biotech has continued this trend with a $350.7 million series D to fuel its various clinical trials.

Risk prevention technology provider LSEG Risk Intelligence has broadened the availability of its Global Account Verification (GAV) service. This solution, initially launched for US customers in ...

The upward trajectory continues for Eikon Therapeutics, which announced that it has raised $351 million to fund various cancer related clinical trials. The Series D funding unveiled Wednesday morning ...